Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.

You may also be interested in...

US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators

Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.

FDA/EU Mutual Reliance For GMP Inspections Moving Forward

Both sides may agree to overlook “areas of divergence” if they don’t appear significant.

ANDA Supplement Review Timeline Hinges On Need For Inspection

FDA notes that it may not be evident right away whether an inspection will be required as part of the review.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts